At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 83 enrolled
Drug / intervention
Standard Dose Bevacizumab +2 moredrug
Likely dose
Standard Dose Bevacizumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) In Adults With Recurrent Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating Standard Dose Bevacizumab, Low Dose Bevacizumab, and 1 other intervention for Brain Cancer and Glioblastoma. Completed, enrolled 83 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if the combination of bevacizumab and lomustine can help to control glioblastoma. The safety of this combination will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Cancer, Glioblastoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedFeb 2010
Primary CompletionOct 2016
TodayJul 2026
First PostedFeb 11, 2010
Enrollment StartJan 1, 2010
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 16.4 years ago
Interventions
Standard Dose Bevacizumabdrug
10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
Low Dose Bevacizumabdrug
5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
Lomustinedrug
Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.